Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health. In addition to traditional drug development, Roivant leverages digital platforms and data-driven tools—such as those developed by its technology affiliate, Datavant—to enhance patient recruitment, real-world evidence collection, and trial analytics. This integrated approach is designed to reduce the cost and time associated with bringing new medicines to market.
Headquartered in Basel, Switzerland, with major offices in New York and London, Roivant Sciences operates on a global scale and collaborates with academic institutions, biotechnology firms, and larger pharmaceutical partners. Its subsidiaries manage their own clinical programs while benefiting from Roivant’s shared infrastructure, regulatory expertise, and commercial strategy. This model allows each “Vant” to maintain a clear focus on its specific therapeutic goal while tapping into centralized support services.
Roivant was founded by entrepreneur Vivek Ramaswamy and is currently led by Chief Executive Officer Matthew Gline. Under their leadership, the company has built a team of experienced biopharma professionals and has raised significant venture and public financing to fuel its pipeline. Through its innovative corporate structure and commitment to technology-enabled development, Roivant continues to pursue its mission of delivering transformative therapies to patients with unmet medical needs.
AI Generated. May Contain Errors.
